Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

direct rx - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 75 mg - - carefully consider the potential benefits and risks of indomethacin extended-release capsules and other treatment options before deciding to use indomethacin extended-release capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). indomethacin extended-release capsules have been found effective in active stages of the following: 1. moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2. moderate to severe ankylosing spondylitis. 3. moderate to severe osteoarthritis. 4. acute painful shoulder (bursitis and/or tendinitis). indomethacin extended-release capsules, usp are not recommended for the treatment of acute gouty arthritis. indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis. in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adver

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

avpak - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - indomethacin 75 mg - carefully consider the potential benefits and risks of indomethacin extended-release capsules and other treatment options before deciding to use indomethacin extended-release capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). indomethacin extended-release capsules have been found effective in active stages of the following: 1. moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2. moderate to severe ankylosing spondylitis. 3. moderate to severe osteoarthritis. 4. acute painful shoulder (bursitis and/or tendinitis). indomethacin extended-release capsules, usp are not recommended for the treatment of acute gouty arthritis. indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis. in such instances the steroid dosag

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 6.935 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - apx-perindopril arginine/ amlodipine is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; magnesium stearate; isomalt; colloidal anhydrous silica; hypromellose; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; isomalt; magnesium stearate; hypromellose; brilliant blue fcf aluminium lake; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.